TY  - JOUR
TI  - Five-Years Tigecycline Experience an Analysis of Real-Life Data
AB  - Aim: Tigecycline has been approved by the Food and DrugAdministration for the treatment of complicated intra-abdominalinfections, skin and soft tissue infections and community-acquiredpneumonia. In our study, we examined the efficacy of tigecycline inclinical practice and reported real life data from our hospital over aperiod of five years.Methods: The study was conducted between 2008 and 2013 onpatients who received tigecycline for longer than 48 hours in AnkaraTraining and Research Hospital. Clinical success was defined as clinicalrecovery and microbiological cure in patients who used tigecycline. Anyreason for discontinuation of tigecycline treatment was considered aclinical failure.Results: In our hospital, 320 patients were administered tigecyclinebetween 2008 and 2013. Tigecycline was mainly used for pneumoniaand skin and soft tissue infections. Tigecycline was used asmonotherapy in 174 patients (54.1%). The most frequently isolatedagent in tigecycline-treated patients was Acinetobacter baumannii(43.4%) followed by Enterococcus (6.9%). A change in treatmentwas not considered necessary in 243 (75.9%) patients who receivedtigecycline, while it was changed in 77 patients (24.1%).Conclusion: In conclusion, the use of tigecycline can be an effectivetreatment choice, either as monotherapy or as a combination antibiotictherapy.
AU  - ILGAR, Tuba
AU  - TÜLEK, Necla Eren
AU  - ATAMAN HATİPOĞLU, Çiğdem
AU  - Temoçin, Fatih
AU  - ERTEM, Günay Tuncer
AU  - BULUT, CEMAL
AU  - ERDINC, Fatma Sebnem
AU  - HEKİMOĞLU, Şirin
AU  - KINIKLI, SAMI
DO  - 10.4274/haseki.42713
PY  - 2018
JO  - Haseki Tıp Bülteni
VL  - 56
IS  - 2
SN  - 1302-0072
SP  - 125
EP  - 130
DB  - TRDizin
UR  - http://search/yayin/detay/297024
ER  -